Latest Operating Expenses News

Everlast Minerals Ltd has successfully completed its IPO, raising $6 million and commencing ASX trading under ticker EV8, setting the stage for advancing its mineral sands projects in Bangladesh.

Temas Resources Corp. has successfully listed on the ASX, raising AU$11 million to advance its patented Regenerative Chloride Leach technology and strategic Québec titanium projects. The move aims to reshape Western critical metals supply chains with cost-effective, sustainable processing solutions.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

DigitalX Limited has enhanced its treasury strategy by investing nearly A$5 million into a market-neutral fund while increasing its Bitcoin holdings to over 500 BTC, aiming to balance accumulation with steady income generation.

Microba Life Sciences reports robust Q1 FY26 growth in microbiome diagnostics, introduces workflow-enhancing features, and prepares for key therapeutic deal catalysts by year-end.

Microba Life Sciences reports a 145% jump in core microbiome test volumes and is on track to achieve regional break-even by FY26, supported by strategic cost cuts and a $14.5 million capital raise.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

BetMakers Technology Group kicks off FY26 with a strong financial turnaround and strategic advances, including a promising acquisition and digital wagering expansion in Nevada.

BetMakers Technology Group has reported a remarkable 361% growth in adjusted EBITDA for Q1 FY26, driven by strong revenue gains and operational efficiencies, while advancing its strategic expansion into the Las Vegas racing market.

ikeGPS has reported a robust first half of FY26 with subscription revenue soaring 47%, a successful A$24 million capital raise, and inclusion in the ASX All Ordinaries Index, underscoring its expanding footprint in the US grid modernization market.

ikeGPS Group reports a robust first half of FY26 with a 47% increase in subscription revenue exit run rate and launches AI-driven PolePilot™ to boost productivity and ARPU.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.